Ming Quan
Overview
Explore the profile of Ming Quan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Ding J, Li S, Jiang A, Chen Z, Quan M
Cell Oncol (Dordr)
. 2025 Feb;
PMID: 39962015
No abstract available.
2.
Liu Y, Ding J, Li S, Jiang A, Chen Z, Quan M
Cell Oncol (Dordr)
. 2025 Feb;
PMID: 39903418
Purpose: The Hippo pathway in the tumorigenesis and progression of PDAC, with lysophosphatidic acid (LPA) regulating the Hippo pathway to facilitate cancer progression. However, the impact of the Hippo signaling...
3.
Tao Z, Chen Z, Zeng X, Cui J, Quan M
Cancer Lett
. 2024 Dec;
611:217433.
PMID: 39736454
The nervous system governs both ontogeny and oncology. Foundational discoveries have clarified the direct communication of neurotransmitters with tumors and indirect interactions through neural effects on the immune system and...
4.
Liu Y, Bischof E, Chen Z, Zhou J, Zhang B, Zhang D, et al.
Oncol Res
. 2024 Sep;
32(9):1429-1438.
PMID: 39220126
Objectives: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have demonstrated potential benefits for metastatic colorectal cancer (mCRC) patients with HER2 amplification, but are not satisfactory in cases of HER2...
5.
Tao Z, Chen Z, Gao Y, Quan M
Cancer Rep (Hoboken)
. 2024 May;
7(5):e2100.
PMID: 38775250
Background: The presence of cancer cachexia is a significant adverse prognostic indicator in patients with malignant tumors. Cancer cachexia is a multifactorial syndrome characterized by a constant loss of skeletal...
6.
Ge W, Wang Y, Quan M, Mao T, Bischof E, Xu H, et al.
Mol Cancer
. 2024 Mar;
23(1):48.
PMID: 38459558
Background: Pancreatic adenocarcinoma (PC) is an aggressive malignancy with limited treatment options. The poor prognosis primarily stems from late-stage diagnosis and when the disease has become therapeutically challenging. There is...
7.
Quan M, Chen J, Chen Z, Hai Y, Zhou Y, Chao Q, et al.
Int J Cancer
. 2023 May;
153(11):1877-1884.
PMID: 37163613
Patients with metastatic colorectal cancer (mCRC) have poor long-term survival. Rechallenge with anti-epidermal growth factor receptor (anti-EGFR) based therapy has shown certain activity as late-line therapy. To further improve clinical...
8.
Li S, Yue M, Xu H, Zhang X, Mao T, Quan M, et al.
Cancer Lett
. 2023 Apr;
564:216206.
PMID: 37120007
Pyroptosis is closely associated with cancer development; however, the role of pyroptosis in pancreatic ductal adenocarcinoma (PDAC), a fatal malignant tumour with a poor overall survival rate, remains elusive. Here,...
9.
Li N, Song H, Chen Z, Chen C, Quan M
Genet Res (Camb)
. 2023 Apr;
2023:1230182.
PMID: 37033161
Salvador homologue 1 (SAV1), which is reported to act as a tumor suppressor in different types of cancer, is one of the key components of the Hippo pathway. However, the...
10.
Li N, Chen Z, Huang M, Zhang D, Hu M, Jiao F, et al.
Front Cell Dev Biol
. 2023 Jan;
10:1035033.
PMID: 36589752
This study aimed to identify fusion partners in Chinese patients with solid tumors. Next-generation sequencing (NGS) analysis was used to detect rearrangement in 45,438 Chinese patients with solid tumors between...